Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases
© 2024. The Author(s)..
BACKGROUND: Drug-induced interstitial lung disease (DILD) is a lung injury caused by various types of drugs and is a serious problem in both clinical practice and drug development. Clinical management of the condition would be improved if there were DILD-specific biomarkers available; this study aimed to meet that need.
METHODS: Biomarker candidates were identified by non-targeted metabolomics focusing on hydrophilic molecules, and further validated by targeted approaches using the serum of acute DILD patients, DILD recovery patients, DILD-tolerant patients, patients with other related lung diseases, and healthy controls.
RESULTS: Serum levels of kynurenine and quinolinic acid (and kynurenine/tryptophan ratio) were elevated significantly and specifically in acute DILD patients. The diagnostic potentials of these biomarkers were superior to those of conventional lung injury biomarkers, Krebs von den Lungen-6 and surfactant protein-D, in discriminating between acute DILD patients and patients with other lung diseases, including idiopathic interstitial pneumonia and lung diseases associated with connective tissue diseases. In addition to identifying and evaluating the biomarkers, our data showed that kynurenine/tryptophan ratios (an indicator of kynurenine pathway activation) were positively correlated with serum C-reactive protein concentrations in patients with DILD, suggesting the potential association between the generation of these biomarkers and inflammation. Our in vitro experiments demonstrated that macrophage differentiation and inflammatory stimulations typified by interferon gamma could activate the kynurenine pathway, resulting in enhanced kynurenine levels in the extracellular space in macrophage-like cell lines or lung endothelial cells. Extracellular quinolinic acid levels were elevated only in macrophage-like cells but not endothelial cells owing to the lower expression levels of metabolic enzymes converting kynurenine to quinolinic acid. These findings provide clues about the molecular mechanisms behind their specific elevation in the serum of acute DILD patients.
CONCLUSIONS: The serum concentrations of kynurenine and quinolinic acid as well as kynurenine/tryptophan ratios are promising and specific biomarkers for detecting and monitoring DILD and its recovery, which could facilitate accurate decisions for appropriate clinical management of patients with DILD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Respiratory research - 25(2024), 1 vom: 14. Jan., Seite 31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Yuchen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
343-65-7 |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 17.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-023-02653-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367121794 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367121794 | ||
| 003 | DE-627 | ||
| 005 | 20240117232205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-023-02653-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1262.xml |
| 035 | |a (DE-627)NLM367121794 | ||
| 035 | |a (NLM)38221627 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Yuchen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 17.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Drug-induced interstitial lung disease (DILD) is a lung injury caused by various types of drugs and is a serious problem in both clinical practice and drug development. Clinical management of the condition would be improved if there were DILD-specific biomarkers available; this study aimed to meet that need | ||
| 520 | |a METHODS: Biomarker candidates were identified by non-targeted metabolomics focusing on hydrophilic molecules, and further validated by targeted approaches using the serum of acute DILD patients, DILD recovery patients, DILD-tolerant patients, patients with other related lung diseases, and healthy controls | ||
| 520 | |a RESULTS: Serum levels of kynurenine and quinolinic acid (and kynurenine/tryptophan ratio) were elevated significantly and specifically in acute DILD patients. The diagnostic potentials of these biomarkers were superior to those of conventional lung injury biomarkers, Krebs von den Lungen-6 and surfactant protein-D, in discriminating between acute DILD patients and patients with other lung diseases, including idiopathic interstitial pneumonia and lung diseases associated with connective tissue diseases. In addition to identifying and evaluating the biomarkers, our data showed that kynurenine/tryptophan ratios (an indicator of kynurenine pathway activation) were positively correlated with serum C-reactive protein concentrations in patients with DILD, suggesting the potential association between the generation of these biomarkers and inflammation. Our in vitro experiments demonstrated that macrophage differentiation and inflammatory stimulations typified by interferon gamma could activate the kynurenine pathway, resulting in enhanced kynurenine levels in the extracellular space in macrophage-like cell lines or lung endothelial cells. Extracellular quinolinic acid levels were elevated only in macrophage-like cells but not endothelial cells owing to the lower expression levels of metabolic enzymes converting kynurenine to quinolinic acid. These findings provide clues about the molecular mechanisms behind their specific elevation in the serum of acute DILD patients | ||
| 520 | |a CONCLUSIONS: The serum concentrations of kynurenine and quinolinic acid as well as kynurenine/tryptophan ratios are promising and specific biomarkers for detecting and monitoring DILD and its recovery, which could facilitate accurate decisions for appropriate clinical management of patients with DILD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Drug-induced interstitial lung diseases | |
| 650 | 4 | |a Kynurenine | |
| 650 | 4 | |a Kynurenine/tryptophan ratio | |
| 650 | 4 | |a Metabolomics | |
| 650 | 4 | |a Quinolinic acid | |
| 650 | 7 | |a Kynurenine |2 NLM | |
| 650 | 7 | |a 343-65-7 |2 NLM | |
| 650 | 7 | |a Tryptophan |2 NLM | |
| 650 | 7 | |a 8DUH1N11BX |2 NLM | |
| 650 | 7 | |a Quinolinic Acid |2 NLM | |
| 650 | 7 | |a F6F0HK1URN |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Saito, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Ushiki, Atsuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kashiwada, Takeru |e verfasserin |4 aut | |
| 700 | 1 | |a Horimasu, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Gemma, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tatsumi, Koichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Tsushima, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Takemoto, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Momiyama, Toshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuyama, Shin-Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Arakawa, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Akane, Hirotoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Kumiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Motonobu |e verfasserin |4 aut | |
| 700 | 1 | |a Takamatsu, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nishiya, Takayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohno, Yasuo |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Yoshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hanaoka, Masayuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 25(2024), 1 vom: 14. Jan., Seite 31 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:14 |g month:01 |g pages:31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-023-02653-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 14 |c 01 |h 31 | ||